Privately held Skyhawk Therapeutics enters into a second collaboration agreement with an affiliate of Celgene (CELG +0.4%) aimed at identifying targets in autoimmune disorders, oncology and immuno-oncology leveraging Skyhawk’s SkySTAR technology platform.
Under the terms of the agreement, Skyhawk will receive $80M upfront, milestones and royalties on net sales. Celgene will have options to exclusively license candidates discovered and developed under the partnership.
The parties inked their first deal in June 2018 for up to five programs.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.